International Journal of Medical and Pharmaceutical Research
2025, Volume-6, Issue-4 : 160-217 doi: 10.5281/zenodo.16416843
Original Article
Role of Early Cholecystectomy Versus Interval Cholecystectomy-In Biliary Pancreatitis
 ,
 ,
Published
July 19, 2025
Abstract

Introduction: Gallstone-related acute pancreatitis is one of the most frequent forms of the condition, accounting for around 40% of all cases. Approximately 3% to 8% of patients with symptomatic gallstones may experience acute pancreatitis, with a higher prevalence among females aged 50–70. Recurrent episodes are common, increasing the risks of complications and mortality.

Materials and Methods: A prospective observational study was conducted from June 1, 2021, to May 31, 2022, including 105 patients with mild to moderate biliary pancreatitis admitted to the Department of Surgery, GMCH. Patients were managed with either early cholecystectomy (<7 days from admission) or delayed cholecystectomy (>6 weeks), based on patient consent. Standard hematological and imaging assessments were performed.

Results: Among the 105 participants, 45 (43%) were male and 60 (57%) female, with the highest incidence (31.4%) in the 51–60 age group. Abdominal pain was universal, followed by vomiting (91%), jaundice (29%), and fever (17%). Early cholecystectomy was performed in 75 patients, and delayed surgery in 30. Hospital stay was significantly shorter and cost lower in the early group, with no readmissions, unlike the delayed group, where 12 readmissions occurred.

Conclusion: Laparoscopic cholecystectomy performed during the initial hospital stay for mild to moderate biliary pancreatitis is safe, effective, and prevents recurrence, making it the preferred approach.

Recommended Articles
Loading Image...
Volume-6, Issue-4
Citations
2539 Views
500 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved